Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
There is high morbidity associated with local recurrence of rectal cancer. However, the adjuvant therapies given to prevent such recurrences also have significant side effects and associated risks. The ability to select patients with the highest risk of recurrence and greatest therapeutic response will improve rectal cancer care.
Myers
Andrea P
AP
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Meyerhardt
Jeffrey A
JA
Cantley
Lewis C
LC
D058534:Class I Phosphatidylinositol 3-Kinases; D015331:Cohort Studies; D003131:Combined Modality Therapy / Q000379:methods; D004252:DNA Mutational Analysis; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism*; D012004:Rectal Neoplasms / Q000235:genetics* / Q000628:therapy; D012008:Recurrence; D016896:Treatment Outcome
D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human